Bright Minds Biosciences Inc.: Form 20-F/A for the period ended Sep 30, 2021
Filed with the SEC on Jan 18, 2022 and accepted by EDGAR at Jan 18, 2022, 16:45 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Income tax | 12 months2020-10-01 to 2021-09-30 | CAD 0 | ifrs-full:IncomeTaxExpenseContinuingOperations |
| Net income | 12 months2020-10-01 to 2021-09-30 | −CAD 8.7m | ifrs-full:ProfitLoss |
| Operating cash flow | 12 months2020-10-01 to 2021-09-30 | −CAD 7.3m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Cash and equivalents | At period end2021-09-30 | CAD 19.8m | ifrs-full:CashAndCashEquivalents |
| Current assets | At period end2021-09-30 | CAD 20.0m | ifrs-full:CurrentAssets |
| Total assets | At period end2021-09-30 | CAD 20.0m | ifrs-full:Assets |
| Total liabilities | At period end2021-09-30 | CAD 638.6k | ifrs-full:Liabilities |
| Shareholders' equity | At period end2021-09-30 | CAD 19.4m | ifrs-full:Equity |
| Shares outstanding | At period end2021-09-30 | 11,834,361 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001062993-22-001182. Last ingested by Listed: Nov 2, 2026, 18:24 ET. Listed shows no prices and gives no investment advice.